The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Things are going from bad to worse for the pharmaceutical giant.

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

Pfizer's lung cancer drug trial update, oncology pipeline strategy, Seagen deal impact, and subgroup opportunity in non small ...

By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 ...

A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.

Pfizer (PFE) stock is in focus as the antibody-drug conjugate sigvotatug vedotin fails in a Phase 3 trial versus chemotherapy ...

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...

Pfizer is drawing healthcare attention as its obesity, oncology, vaccine, and medicine programs shape a broader pipeline ...